Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Maven Biotechnologies

Maven Biotechnologies

A life science instrumentation company developing ellipsometry analysis systems for microplates and slide disposables

Maven Biotechnology is a California based biotechnology company which develops real-time and label-free imaging technology for protein microarrays, cell-based assays, and multiplex biomarker detection for microplates and disposable slides. The diagnostic technology can include quantitative or qualitative determination of hormones, drugs, metabolic products, tumor markers, autoimmune auto-antibodies, vitamins, and disease agents in biological fluids.


Label Free Internal Reflection Ellipsometry or LFIRE is a real-time polarimetric imaging technology which uses a beam of polarized light directed from the underside of a piece of glass at a specific “critical” angle which is then reflected by the glass-water interface. The reflection produces an electromagnetic wave that responds to the refractive index in the water. A camera with a 12 bit-sensor is used to capture and measure the reflected light beam in real time. The polarization of the reflected beam changes in real time with respect to what the light beam comes in contact with at the interface, which changes its refractive index. This change in polarization allows it to detect small molecules, protein or even cells.

The company’s initial target is immunoassays including various antigen-antibody and kinetic analysis, HCG (Human Chorionic Gonadotropin), species-specific and isotype-specific industrial secondary antibodies. The system can also target autoimmune antigens and infectious disease antigens.


William R. Rassman founded the company in 2000 and is headquartered in Pasadena, California.


December 8, 2011
Maven to Leverage Sony DADC Technology in Label-Free Detection | GEN - Genetic Engineering and Biotechnology News

Sony DADC BioSciences and Maven Biotechnologies entered a collaboration to develop and manufacture smart consumables for Maven’s Lfire™ detection platform

October 1, 2010
Maven Biotechnologies awarded $1.96 million by the National Institute for Allergy and Infectious Disease

To support the commercialization of the LFIRE™ imaging technology for label-free protein microarrays and cell-based assays

October 2010
Maven Biotechnologies raises a $2,000,000 grant from National Institutes of Health.

Funding rounds


Further Resources



Golden logo
By using this site, you agree to our Terms & Conditions.